In a decision entered Friday, December 12, 2014, two dozen lawsuits concerning the blood thinning drug Xarelto were consolidated in Louisiana federal court by the U.S. Judicial Panel on Multidistrict Litigation (MDL). An MDL can accelerate proceedings in a more effective manner, and can also help gauge how juries will respond to evidence and testimony that is likely to be repeated throughout future litigation. The Judicial Panel held that the suits alleged enough common factual questions about Janssen Pharmaceuticals Inc. and Bayer Corp.’s drug to warrant consolidation, including whether the drug’s label sufficiently warned its users of potentially fatal bleeding side effects. “While we agree that these actions present a number of individualized factual issues,” the panel noted in its order, “the existence of such issues do not negate the common ones.” Consolidating these cases boasts the benefits of saving time and costs, and represents a step forward in the effort to obtain relief plaintiffs’ deserve after experiencing negative side effects when taking Xarelto.